3-BroMo-4-azaindole-6-carboxylic acid
|
- $392 - $1019.2
- Product name: 3-BroMo-4-azaindole-6-carboxylic acid
- CAS: 1190322-94-1
- MF: C8H5BrN2O2
- MW: 241.04
- EINECS:
- MDL Number:MFCD12963067
- Synonyms:3-BroMo-4-azaindole-6-carboxylic acid;3-BROMO-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXYLIC ACID;1H-Pyrrolo[3,2-b]pyridine-6-carboxylic acid, 3-bromo-
4 prices
Selected condition：
Brand
- Alichem
- Crysdot
Package
- 250mg
- 1g
- ManufacturerAlichem
- Product number1190322941
- Product description3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid
- Packaging250mg
- Price$431.2
- Updated2021-12-16
- Buy
- ManufacturerAlichem
- Product number1190322941
- Product description3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid
- Packaging1g
- Price$1019.2
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11335216
- Product description3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid 97%
- Packaging250mg
- Price$392
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11335216
- Product description3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid 97%
- Packaging1g
- Price$980
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Alichem | 1190322941 | 3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid | 250mg | $431.2 | 2021-12-16 | Buy |
| Alichem | 1190322941 | 3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid | 1g | $1019.2 | 2021-12-16 | Buy |
| Crysdot | CD11335216 | 3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid 97% | 250mg | $392 | 2021-12-16 | Buy |
| Crysdot | CD11335216 | 3-Bromo-1H-pyrrolo[3,2-b]pyridine-6-carboxylicacid 97% | 1g | $980 | 2021-12-16 | Buy |
Properties
Boiling point :506.9±45.0 °C(Predicted)
Density :1.946±0.06 g/cm3(Predicted)
pka :2.22±0.30(Predicted)
Density :1.946±0.06 g/cm3(Predicted)
pka :2.22±0.30(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|